Stay up to date with the latest developments and advances in HR+/HER2- early breast cancer care with content from key international congresses, expert-to-expert video discussions and breaking news stories.
medwireNews: Temporarily withholding adjuvant endocrine therapy (ET) to attempt pregnancy does not adversely impact the short-term disease outcomes of women with hormone receptor-positive early breast cancer, indicate POSITIVE data.…
medwireNews: Interim analysis of the monarchE trial indicates that the invasive disease-free survival (iDFS) benefits of adding adjuvant abemaciclib to endocrine therapy have strengthened after 4 years of follow-up in…
medwireNews: Non-Hispanic Black women with hormone receptor-positive, HER2-negative, early breast cancer have worse outcomes than their non-Hispanic White counterparts despite similar genetic risk and treatment adherence in the first year,…
medwireNews: The 21-gene expression assay may be a poor prognostic aid for premenopausal women aged less than 40 years with luminal B subtype, hormone receptor-positive, HER2-negative early breast cancer, indicates…
medwireNews: Analysis of the monarchE trial suggests that an increase in the burden of diarrhea is the only patient-reported outcome (PRO) to be adversely affected by the addition of abemaciclib…
medwireNews: Dose-dense adjuvant chemotherapy significantly improves the outcomes of individuals with node-positive, early-stage breast cancer relative to the standard schedule, confirm the end-of-study findings from GIM2 presented at the ESMO…
medwireNews: The 10-year findings from the DATA trial have shown no significant benefit of extending aromatase inhibitor (AI) treatment beyond 5 years of sequential therapy in the full study population…
medwireNews: The monarchE investigators have identified baseline factors linked to an increased risk for discontinuation of abemaciclib in the trial comprising patients with hormone receptor-positive, HER2-negative early breast cancer.…
medwireNews: Plasma circulating tumor (ct)DNA analysis could help identify patients with hormone receptor (HR)-positive, HER2-negative early breast cancer who are likely to have distant recurrence at 5 years or more after…
Sign up for new content alerts
Enter your email address below and we'll contact you as soon as new content is launched!
